Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SCIENCE 37 HOLDINGS, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 4.93 USD | +2.71% | -1.40% | -40.63% | |
| Nov. 07 | Science 37 Holdings, Inc. Provides Revenue Guidance for the Full Year 2024 | CI |
| Nov. 07 | Transcript : Science 37 Holdings, Inc., Q3 2023 Earnings Call, Nov 07, 2023 | CI |
Financials (USD)
| Sales 2023 * | 58.3M | Sales 2024 * | 65.98M | Capitalization | 29.43M |
|---|---|---|---|---|---|
| Net income 2023 * | -71M | Net income 2024 * | -35M | EV / Sales 2023 * | -0,36x |
| Net cash position 2023 * | 50.18M | Net cash position 2024 * | 21.78M | EV / Sales 2024 * | 0,12x |
| P/E ratio 2023 * | -0,40x | P/E ratio 2024 * | -0,86x | Employees | 460 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 4.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.71% | ||
| 1 week | -1.40% | ||
| Current month | -2.61% | ||
| 1 month | -14.23% | ||
| 3 months | -7.33% | ||
| 6 months | -17.23% | ||
| Current year | -40.63% |
1 week
3.93
5.34
1 month
3.935.98
Current year
3.8013.80
1 year
3.8013.80
3 years
3.80302.06
5 years
3.80302.06
10 years
3.80302.06
| Managers | Title | Age | Since |
|---|---|---|---|
David Coman
CEO | Chief Executive Officer | 53 | 2019 |
Mike Zaranek
DFI | Director of Finance/CFO | 51 | 2021 |
Jonathan Cotliar
CTO | Chief Tech/Sci/R&D Officer | 52 | 2019 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Faulkner
CHM | Chairman | 60 | 2021 |
David Coman
CEO | Chief Executive Officer | 53 | 2019 |
John Hubbard
BRD | Director/Board Member | 66 | 2021 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 281,588 M€ | +19.70% | ||
| 0.00% | 4,253 M€ | +20.05% | - | |
| 0.00% | 499 M€ | +18.39% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 4.93 | +2.71% | 59,810 |
| 23-12-07 | 4.8 | -6.98% | 21,210 |
| 23-12-06 | 5.16 | +11.21% | 19,484 |
| 23-12-05 | 4.64 | -7.20% | 68,124 |
| 23-12-04 | 5 | 0.00% | 18,359 |
Delayed Quote Nasdaq, December 08, 2023 at 04:00 pm EST
More quotes
Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. It also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. It uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
Sector
Software
Calendar
2024-03-18
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.93USD
Average target price
28.75USD
Spread / Average Target
+483.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.63% | 29 M $ | |
| +56.05% | 2781 B $ | |
| +67.85% | 81 506 M $ | |
| +61.81% | 70 717 M $ | |
| +32.02% | 62 479 M $ | |
| +49.49% | 49 640 M $ | |
| +176.79% | 38 667 M $ | |
| +57.55% | 34 630 M $ | |
| +49.16% | 26 415 M $ | |
| +43.46% | 25 467 M $ |
